<DOC>
	<DOCNO>NCT02461316</DOCNO>
	<brief_summary>Evaluation safety profile tolerability MabThera ( rituximab ) combination chemotherapy ( fludarabine cyclophosphamide ) treatment Chronic Lymphocytic Leukemia ( CLL ) .</brief_summary>
	<brief_title>Rituximab Combination With Fludarabine Cyclophosphamide Patients With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Patients older 18 year diagnose Chronic Lymphocytic Leukemia ( CLL ) CLL stage : Binet stage C ( Rai III IV ) , Binet stage B ( Rai I II ) require treatment Patients eligible rituximab treatment accord Summary Product Characteristics ( SmPC )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>